Quarterly ResultJun 10, 2026, 04:23 PM
Anixa Biosciences Reports Q2 2026 Results: Net Loss Decreases to $5.12M
AI Summary
Anixa Biosciences Inc. filed its 10-Q report for the period ending April 30, 2026. The company reported a net loss of $5.121 million for the six months ended April 30, 2026, a decrease from $6.026 million in the same period last year. Total assets and shareholders' equity saw a decrease, while liabilities also reduced. The company raised approximately $2.870 million through an at-the-market equity offering and continued to invest in research and development, with R&D expenses totaling $2.360 million for the six-month period.
Key Highlights
- Anixa Biosciences reported a net loss of $5.121 million for the six months ended April 30, 2026, compared to $6.026 million in the prior year.
- Total assets decreased to $14.865 million as of April 30, 2026, from $16.080 million as of October 31, 2025.
- Total liabilities decreased to $1.641 million as of April 30, 2026, from $2.130 million as of October 31, 2025.
- Shareholders' equity stood at $14.475 million as of April 30, 2026, down from $15.161 million as of October 31, 2025.
- Cash used in operating activities was $4.351 million for the six months ended April 30, 2026.
- The company raised $2.870 million through an at-the-market equity offering during the six months ended April 30, 2026.
- Research and development expenses for the six months ended April 30, 2026, were $2.360 million.
- General and administrative expenses for the six months ended April 30, 2026, were $3.003 million.
Price Impact